BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Rogers JR, Pavisic J, Ta CN, Liu C, Soroush A, Kuen Cheung Y, Hripcsak G, Weng C. Leveraging Electronic Health Record Data for Clinical Trial Planning by Assessing Eligibility Criteria’s Impact on Patient Count and Safety. Journal of Biomedical Informatics 2022. [DOI: 10.1016/j.jbi.2022.104032] [Reference Citation Analysis]
2 Balcar L, Semmler G, Pomej K, Simbrunner B, Bauer D, Hartl L, Jachs M, Paternostro R, Bucsics T, Pinter M, Trauner M, Mandorfer M, Reiberger T, Scheiner B. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. United European Gastroenterol J 2021;9:427-37. [PMID: 34050619 DOI: 10.1002/ueg2.12089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
4 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int 2021;41:1999-2008. [PMID: 34242466 DOI: 10.1111/liv.15013] [Reference Citation Analysis]
7 Allegretti AS, Jamil K, Moore K. Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply. Aliment Pharmacol Ther 2021;54:350-1. [PMID: 34236097 DOI: 10.1111/apt.16486] [Reference Citation Analysis]